BIO.News Newsletter

New studies find COVID vaccine misinformation is growing, and heat-related cardiovascular deaths could be increasing. Biotech has solutions for both challenges. (536 words, 2 minutes, 40 seconds)

Today, we look at what happened during yesterday’s FDA advisory panel review of exa-cel, and a recently reintroduced bill that would support tax incentives for biofuels with more accurate measures of carbon reduction. (452 words, 2 minutes, 15 seconds)

Happy Halloween. A scary proposed rule on Medicaid drug coverage would harm patient access. Plus, today’s new episode of the I am BIO Podcast explores the possibilities of synbio. (568 words, 2 minutes, 50 seconds)

BIO member Dalan Animal Health’s honeybee vaccine is generating buzz—here’s why. Plus, a D.C.-area man has been named “Miracle Man” after surviving sepsis, but he now needs a kidney. We tell you his story and why developing new antimicrobials matters. (423 words, 2 minutes, 6 seconds)

A busy week on Capitol Hill concluded with visits by BIO members and the introduction of the Senate’s version of the ORPHAN Cures Act. (435 words, 2 minutes, 10 seconds)

It’s all about BIO thought leadership today—explaining the impact of PBMs and price controls on generics, and why we need to pass the Farm Bill to advance needed biotech solutions. (482 words, 2 minutes, 24 seconds)

It’s a CMS-heavy day, as we look at what patient advocates are saying about Medicaid, and what CMS itself is saying about what’s driving Medicare premium increases. (694 words, 3 minutes, 28 seconds)

We recap Day 1 of the BIO Patient & Health Advocacy Summit in D.C. with a look at the unintended consequences of the Inflation Reduction Act—and why patients must be centered. And this World Polio Day, we see an opportunity to eradicate polio worldwide—if we continue vaccination efforts. (643 words, 3 minutes, 12 seconds)

We’re live in Washington, D.C., for BIO’s Patient & Health Advocacy Summit—watch here for highlights. Meanwhile, we look at proposed changes to Medicaid drug coverage and FTC’s merger guidelines, and what they mean for biotech innovation. (567 words, 2 minutes, 50 seconds)

Closing out a busy week with a preview of today’s US — EU Summit and how biotech is boosting beer production—plus, what you missed at the BIO Investor Forum in San Francisco. (680 words, 3 minutes, 24 seconds)